key: cord-0768295-8japln9z authors: Wise-Draper, T. M.; Desai, A.; Elkrief, A.; Rini, B. I.; Flora, D. B.; Bowles, D. W.; Shah, D.; Rivera, D.; Johnson, D. B.; Lopes, G.; Grivas, P.; Thompson, M. A.; Peters, S.; Kuderer, N. M.; Nock, N. L.; Grover, P.; Li, X.; Gulati, S.; Choueiri, T. K.; Warner, J. title: Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis date: 2020-09-30 journal: Annals of Oncology DOI: 10.1016/j.annonc.2020.08.2312 sha: c7c1c9dd000bf2a67d4dec9e9731246db81758b8 doc_id: 768295 cord_uid: 8japln9z Background: SARS-CoV-2 is associated with diverse clinical presentations ranging from asymptomatic infection to lethal complications. Small studies have suggested inferior outcomes in patients (pts) on active cancer treatment. This finding was not independently validated in our prior report on 928 pts, which included treatments administered within 4 weeks of COVID-19 diagnosis. Here, we examine outcomes related to systemic cancer treatment within one year of lab-confirmed SARS-CoV-2 infection in an expanded cohort. Method(s): The COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) was queried for pts ever receiving systemic treatment. Treatment type, cancer type, stage, and COVID-19 outcomes were examined. Pts were stratified by time from last treatment administration: <2 wk, 2-4 wk, 1-3 mo, or 3-12 mo. Standardized incidence ratios (SIR) of mortality by treatment type and timing were calculated. Result(s): As of 31 July 2020, we analyzed 3920 pts;42% received systemic anti-cancer treatment within 12 mo (Table). 159 distinct medications were administered. The highest rate of COVID-19-associated complications were observed in pts treated within 1-3 months prior to COVID-19;all-cause mortality in this group was 26%. 30-day mortality by most recent treatment type was 20% for chemotherapy, 18% for immunotherapy, 17% for chemoradiotherapy, 29% for chemoimmunotherapy, 20% for targeted therapy, and 11% for endocrine therapy. SIR of mortality was highest for chemoimmunotherapy or chemotherapy <2 wks, and lowest for endocrine treatments. A high SIR was also found for targeted agents within 3-12 mo. Pts untreated in the year prior to COVID-19 diagnosis had a mortality of 14%. [Formula presented] Conclusion(s): 30-day mortality was highest amongst cancer pts treated 1-3 months prior to COVID-19 diagnosis and those treated with chemoimmunotherapy. Except for endocrine therapy, mortality for subgroups was numerically higher than in pts untreated within a year prior to COVID-19 diagnosis. Clinical trial identification: NCT04354701. Legal entity responsible for the study: The COVID-19 and Cancer Consortium (CCC19). Funding(s): National Cancer Institute (P30 CA068485). Disclosure: T.M. Wise-Draper: Research grant/Funding (self), Travel/Accommodation/Expenses: AstraZeneca;Research grant/Funding (self): BMS;Research grant/Funding (self): Tesaro/GSK;Advisory/Consultancy: Shattuck Labs;Leadership role, Travel/Accommodation/Expenses, HNC POA Lead: Caris Life Sciences;Research grant/Funding (self), Travel/Accommodation/Expenses: Merck;Travel/Accommodation/Expenses: Eli Lilly;Travel/Accommodation/Expenses: Bexion. A. Elkrief: Research grant/Funding (self): AstraZeneca. B.I. Rini: Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Merck;Advisory/Consultancy, Research grant/Funding (self): Roche;Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Pfizer;Advisory/Consultancy, Research grant/Funding (self): AVEO;Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: BMS;Advisory/Consultancy: arravive;Advisory/Consultancy: 3D medicines;Advisory/Consultancy: Synthorx;Advisory/Consultancy: Surface Oncology;Shareholder/Stockholder/Stock options: PTC Therapeutics;Research grant/Funding (self): AstraZeneca. D.B. Johnson: Advisory/Consultancy: Array Biopharma;Advisory/Consultancy, Research grant/Funding (self): BMS;Advisory/Consultancy: Janssen;Advisory/Consultancy: Merck;Advisory/Consultancy: Novartis;Research grant/Funding (self): Incyte;Leadership role: ASCO melanoma scientific committee chair;Leadership role: NCCN Melanoma committee. G. Lopes: Honoraria (self), Travel/Accommodation/Expenses: Boehringer Ingelheim;Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer;Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): AstraZeneca;Research grant/Funding (institution): Merck;Research grant/Funding (institution): EMD Serono;Research gr Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis Background: SARS-CoV-2 is associated with diverse clinical presentations ranging from asymptomatic infection to lethal complications. Small studies have suggested inferior outcomes in patients (pts) on active cancer treatment. This finding was not independently validated in our prior report on 928 pts, which included treatments administered within 4 weeks of COVID-19 diagnosis. Here, we examine outcomes related to systemic cancer treatment within one year of lab-confirmed SARS-CoV-2 infection in an expanded cohort. The COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) was queried for pts ever receiving systemic treatment. Treatment type, cancer type, stage, and COVID-19 outcomes were examined. Pts were stratified by time from last treatment administration: <2 wk, 2-4 wk, 1-3 mo, or 3-12 mo. Standardized incidence ratios (SIR) of mortality by treatment type and timing were calculated. Results: As of 31 July 2020, we analyzed 3920 pts; 42% received systemic anti-cancer treatment within 12 mo (Table) . 159 distinct medications were administered. The highest rate of COVID-19-associated complications were observed in pts treated within 1-3 months prior to COVID-19; all-cause mortality in this group was 26%. 30day mortality by most recent treatment type was 20% for chemotherapy, 18% for immunotherapy, 17% for chemoradiotherapy, 29% for chemoimmunotherapy, 20% for targeted therapy, and 11% for endocrine therapy. SIR of mortality was highest for chemoimmunotherapy or chemotherapy <2 wks, and lowest for endocrine treatments. A high SIR was also found for targeted agents within 3-12 mo. Pts untreated in the year prior to COVID-19 diagnosis had a mortality of 14%. Conclusions: 30-day mortality was highest amongst cancer pts treated 1-3 months prior to COVID-19 diagnosis and those treated with chemoimmunotherapy. Except for endocrine therapy, mortality for subgroups was numerically higher than in pts untreated within a year prior to COVID-19 diagnosis. Clinical trial identification: NCT04354701. Legal entity responsible for the study: The COVID-19 and Cancer Consortium (CCC19). Funding: National Cancer Institute (P30 CA068485). Travel/Accommodation/Expenses, Shareholder/Stockholder/Stock options: Doximity Travel/Accommodation/Expenses: Syapse; Licensing/Royalties: Uptodate. S. Peters: Honoraria (self), Honoraria (institution), Advisory/Consultancy: AbbVie Advisory/Consultancy, Research grant/Funding (self): Amgen; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses Honoraria (self), Honoraria (institution), Advisory/Consultancy: Bayer Advisory/Consultancy: Biocartis; Honoraria (self), Honoraria (institution), Advisory/Consultancy: Bioinvent Advisory/ Consultancy: Blueprint Medicines Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self): Boehringer-Ingelheim Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Bristol-Myers Squibb Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/ Funding (self): Clovis Honoraria (self), Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Daiichi Sankyo Honoraria (self), Honoraria (institution), Advisory/Consultancy: Debiopharm Honoraria (self), Honoraria (institution), Advisory/Consultancy Advisory/Consultancy, Research grant/Funding (self), Travel/ Accommodation/Expenses: F. Hoffmann-La Roche Honoraria (self), Honoraria (institution) Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Ilumina; Honoraria (self), Honoraria (institution) Advisory/Consultancy, Research grant/Funding (self), Travel/Accommodation/Expenses: Merck Sharp and Dohme Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self) Honoraria (self), Honoraria (institution), Advisory/Consultancy: Merrimack Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self): Novartis Advisory/Consultancy: PharmaMar; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Research grant/Funding (self): Pfizer; Honoraria (self), Honoraria (institution), Advisory/Consultancy: Regeneron Honoraria (self), Honoraria (institution), Advisory/Consultancy: Sanofi Honoraria (self), Honoraria (institution), Advisory/Consultancy Honoraria (self), Honoraria (institution), Advisory/Consultancy: Takeda Advisory/Consultancy: Vaccibody Advisory/Consultancy: Celldex Advisory/Consultancy: Invitae Advisory/Consultancy: Total Health Advisory/Consultancy: Beyond Springs Advisory/Consultancy: BAyer Advisory/Consultancy: Spectrum Pharmaceuticals. S. Gulati: Advisory/Consultancy: Puma Biotechnology Research grant/Funding (self): AstraZeneca; Research grant/Funding (self): IsoRay. T.K. Choueiri: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self Advisory/Consultancy, Research grant/Funding (self): Alexion; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self Advisory/ Consultancy, Research grant/Funding (self): BMS Advisory/Consultancy, Research grant/Funding (self): Cerulean Advisory/Consultancy, Research grant/Funding (self): Eisai Advisory/Consultancy, Research grant/Funding (self): Foundation Medicine Advisory/Consultancy, Research grant/Funding (self): Exelixis Research grant/Funding (self): Ipsen; Research grant/Funding (self): Tracon Advisory/Consultancy, Research grant/Funding (self): Genentech Advisory/ Consultancy, Research grant/Funding (self): Roche Advisory/Consultancy, Research grant/Funding (self): GSK Advisory/Consultancy, Research grant/Funding (self Advisory/Consultancy, Research grant/Funding (self): Merck Advisory/Consultancy, Research grant/Funding (self): Novartis Advisory/Consultancy, Research grant/Funding (self): Peloton Advisory/Consultancy, Research grant/Funding (self Advisory/Consultancy, Research grant/Funding (self): Promethius Labs Research grant/Funding (self): Corvus; Research grant/ Funding (self): Calithera Advisory/Consultancy, Research grant/Funding (self) Research grant/Funding (self): Sanofi/Aventis; Research grant/ Funding (self): Takeda Honoraria (self) Honoraria (self): Navinata Healthcare; Honoraria (self), Advisory/Consultancy: NCCN MJH) Associates, Inc (Healthcare Communications Company with several brands such as OnClive Honoraria (self): Research to Practice Advisory/Consultancy: BM Watson Health Advisory/Consultancy: westat; Leadership role, Shareholder/Stockholder/ Stock options: HemOnc.org LLC All other authors have declared no conflicts of interest LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19) Division of Cancer Control and Population Sciences The impact of clinicopathologic factors, cancer type, stage or therapies on outcomes of pts with COVID19 is not well defined. We systematically and comprehensively identified and assessed factors associated with high mortality (M) in the largest cohort of pts with cancer and COVID-19 Analysis was limited to lab-confirmed COVID-19. Primary endpoint: all-cause 30-day M. Multivariable logistic regression was used to assess association between 30-day M and a priori identified demographic/clinicopathologic risk factors (age, sex, race, region, smoking, obesity, comorbidities, ECOG PS, cancer status, recent In 3830 pts with lab confirmed COVID19, 30-day M was 14% overall and 23% in hospitalized pts. Table shows adjusted [a]OR for overall and hospitalized pts. Age, male sex, smoking, >2 comorbidities, ECOG PS1, progressive cancer, hematologic or >1 cancer, and severe baseline COVID19 at presentation were associated with worse 30-day M OVERall (N[3819) Hospitalized (N[2168)